O023/#1012 Cancer Screening in Transgender Men in the United States: is There a Disparity? – A Us Brfss Study

Objectives To determine the rate of cancer screening for breast and cervical cancer in transgender patients in the United States. Methods Data were obtained from the Behavioral Risk Factor Surveillance System (BRFSS) from 2014–2017. Chi square tests were used for statistical analysis. Results Of 204,535 participants, 216 (0.11%) self reported as transgender male-to-female (TMF), 324 (0.16%) transgender female to male (TFM), 148 (0.07%) transgender non-conforming (TNC), and 201,061 (98.3%) as non-transgender females (NTF). 13.6% of TFM patients reported they had never had cervical screening, compared to 5.7% of NTF patients (p<0.01). This was most apparent with younger participants, with only 50% of TFM patients between 18–29 reporting having had cervical screening compared to 70% of NTF patients (p=0.011). 69.9% (n=181) of TFM patients reported having a mammogram in the last two years, compared to 72.5% (n=120,148) of NTF females (p=0.24). This disparity was greater in the younger population, with 58.8% (n=30) of TFM patients age 40–49 meeting this guideline, compared to 66.0% (n=16,669) of NTF patients (p<0.001). For colon cancer screening, 67.1% of TFM patients (n=186) reported ever having a colonoscopy or sigmoidoscopy compared to 73.0% (n=172,298) of NTF patients (p=0.03). Conclusions Transgender female-to-male patients were significantly less likely to undergo cancer screening compared to non-transgender patients. These trends were most noticeable for cancer screening specific to female organs, including cervical cancer screening and mammograms.